Cellectar Biosciences Reports Third Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights

MADISON, Wis., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB ), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the third quarter 2014.

Recent Highlights:

  • Publication detailing efficacy of Cellectar's proprietary phospholipid ether (PLE) analog agents for the detection, imaging and real-time visualization of colorectal cancer was published in PLOS ONE , an international, peer-reviewed publication
  • U.S. Food & Drug Administration (FDA) accepted the Company's investigational new drug (IND) application to evaluate I-131-CLR1404 in clinical trials in relapsed or refractory multiple myeloma, an incurable cancer of plasma cells
  • Completed underwritten public offering generating gross proceeds of $13.5 million, before deducting underwriting discounts and commissions and other offering expenses
  • Extinguished all outstanding debt and related accrued interest associated with the February 2014 private placement of convertible debentures in exchange for common shares and warrants in conjunction with the underwritten offering
  • Secured listing of common stock on Nasdaq Capital Market under the ticker CLRB

"Over the past few months, we have worked to develop a program that could showcase the potential therapeutic benefit of our highly-targeted, cancer-selective radiopharmaceutical, I-131-CLR1404. We believe relapsed or refractory multiple myeloma not only provides this opportunity but represents a medical need in which we believe our therapeutic could be impactful. With the recent acceptance of our IND, we are now working with our lead investigator and site staff to initiate our first therapeutic trial in this indication," commented Dr. Simon Pedder, Cellectar's president and chief executive officer. "In addition to progress made across our pipeline during the third quarter, we are pleased to have also significantly strengthened our balance sheet. With this infusion of capital, new Nasdaq listing and a robust line-up of clinical programs, we are well-positioned to make 2015 a transformative year for Cellectar."

Financial Results for the Quarter and Nine Months Ended September 30, 2014:

Cellectar reported a net loss for the quarter ended September 30, 2014 of $0.5 million or ($0.10) per share compared with a net loss of $1.3 million or ($0.46) per share reported for the comparable period in 2013. For the first nine months of 2014, Cellectar reported a net loss of $5.5 million or ($1.54) per share compared to a net loss of $6.8 million or ($2.47) per share for the nine months ended September 30, 2013.

Research and development (R&D) expenses for the quarter ended September 30, 2014 were $1.5 million, compared to $2.1 million for the third quarter of 2013. For the nine months ended September 30, 2014, Cellectar's research and development expenses were $4.6 million compared to $5.3 million during the first nine months of 2013.

Cellectar's general and administrative (G&A) expenses were essentially unchanged year-over-year with third quarter 2014 G&A expenses totaling $0.8 million. Similarly, G&A expenses for the nine months ended September 30, 2014 were $2.8 million compared to $3.0 million for the comparable period in 2013.

Cellectar ended the quarter with $11.6 million in cash and cash equivalents compared to $2.4 million in cash and cash equivalents at December 31, 2013.

On August 20, 2014, Cellectar completed an underwritten offering of shares and warrants that generated new gross proceeds of $13.5 million. The proceeds of this offering will be used for further research and development of Cellectar's pipeline. Cellectar anticipates that the cash and cash equivalents at quarter-end combined with net proceeds from its August offering will fund the company's planned research and development programs into the fourth quarter 2015.

Event Details:

Interested investors may participate in the conference call by dialing 888-646-8293 (domestic) or 973-453-3065 (international). A replay will be available for one week following the call by dialing 855-859-2056 for domestic participants or 404-537-3406 for international participants and entering conference ID 32168812 when prompted. Participants may also access both the live and archived webcast of the conference call on the investor relations section of Cellectar's web site, www.cellectar.com .

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar's compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to "find, treat and follow" malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com .

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.   These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTOR CONTACT Kate McNeil, Vice President of IR, PR & Corporate Communications Cellectar Biosciences, Inc. Phone: (347) 204-4226 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 86

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 152

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 89

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 18

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 44

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 162

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 64

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading

Top 5 Most Recently Viewed Articles

Uptown Cheapskate and Kid to Kid Shaping the Resale Future

Updated Category News Views 413

Innovating the Resale Landscape with Uptown Cheapskate and Kid to Kid BaseCamp Franchising is witnessing a remarkable transformation in the retail sector through its brands, Uptown Cheapskate and Kid to Kid. With over 260 stores across various U.S. states and additional international locations, these brands are redefining thrift shopping by merging the thrill of the hunt...

Continue Reading
Midea's Indoor Hybrid Heat Pump Revolutionizes Home Heating

Updated Category News Views 348

Midea’s Innovative CirQHP Indoor Hybrid Heat Pump Midea, a well-known leader in the HVAC industry, has unveiled its latest creation: the CirQHP Indoor Hybrid heat pump. This cutting-edge system has been honored with the Innovative Heating Technology Gold Award at an international exhibition. The CirQHP Indoor Hybrid allows homeowners to enjoy a modern heating solution...

Continue Reading
Exploring NYC's Future Guaranteed Income Program for Residents

Updated Category News Views 168

New York City’s Guaranteed Income Initiative New York City is embarking on a transformative journey to introduce a guaranteed income program aimed at helping those in need. Planned for 2026, this program will distribute $15,800 annually to residents who are facing economic hardships. It's an innovative approach to addressing poverty and housing insecurity within the...

Continue Reading
Investigating Potential Shareholder Dilemmas for TXNM, STRR, PVBC

Updated Category News Views 145

Understanding Shareholder Rights and Legal Investigations In the evolving landscape of corporate mergers and acquisitions, shareholder rights play a crucial role. Many companies are involved in significant transactions that raise questions for their shareholders. Today, we explore multiple companies undergoing scrutiny due to potential violations related to shareholder...

Continue Reading
Legal Battle Unfolds as U.S. Steel and Nippon Steel Challenge Biden

Updated Category News Views 215

U.S. Steel and Nippon Steel Challenge Government Actions United States Steel Corp (NYSE: X) and Nippon Steel Corp have taken significant legal steps against the Biden administration after the President's decision to block their ambitious $14.9 billion merger. This action by the government has raised questions about the motivations behind the blockade. The Legal Actions...

Continue Reading